ClinicalTrials.gg
Active, not recruitingNCT06924970Updated Oct 28, 2026

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

A Phase 2 interventional study of Tebapivat and Tebapivat Matched Placebo in Sickle Cell Disease, sponsored by Agios Pharmaceuticals, Inc.. Active, not recruiting at 20 sites in 7 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Agios Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
172nd of 559
59 · median 31
Started
2025
with 33 others
Phase 2
161 of 733
23 open now
Primary completion
2026-05
later than 34 of 182 live
Registered
686th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 172nd largest by enrollment of the 559 interventional ones that give a count, is one of 34 that started in 2025, is one of 161 in phase 2, reaches primary completion later than 34 of the 182 other live ones, and was the 686th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Documented diagnosis of SCD (HbSS, HbSC [combined heterozygosity for hemoglobins S and C], sickle [HbS]/β0-thalassemia, HbS/β+-thalassemia, or other sickle cell syndrome variants).
  • Hemoglobin ≥5.5 and ≤10.5 grams per decilitre (g/dL). Hemoglobin concentration must be based on an average of at least 2 Hb concentration measurements (separated by ≥7 days) collected during the screening period.
  • If taking hydroxyurea, the hydroxyurea dose must be stable for at least 90 days before randomization. Discontinuation of hydroxyurea requires a 90-day before providing .

Key Exclusion Criteria:

  • Receiving regularly scheduled red blood cell (RBC) transfusion therapy (also termed chronic, prophylactic, or preventative transfusion); episodic transfusion in response to worsened anemia or vaso-occlusive crisis (VOC) is permitted. Additionally, a participant who requires episodic transfusion(s) may not have received a transfusion(s) within 60 days before providing informed consent or during the screening period.
  • >10 sickle cell pain crisis (SCPCs) in the 12 months before providing informed consent.
  • Receiving anabolic steroids that have not been stopped for at least 4 weeks before randomization. Testosterone replacement therapy to treat hypogonadism is allowed; the testosterone dose and preparation must be stable for ≥10 weeks before randomization.
  • Hospitalized for an SCPC and/or other vaso-occlusive event within 14 days before providing informed consent or within 14 days before randomization. If an SCPC occurs during the screening period, the screening period may be extended with Medical Monitor approval.
  • Receiving treatment with voxelotor, crizanlizumab, or L-glutamine within 90 days before randomization.
  • count \<lower limit of normal (LLN) for the local laboratory or \<150×109/liter (L) (whichever is lower) during screening. Platelet transfusions received within 28 days before consent or during screening.
  • Receiving treatment with hematopoietic stimulating agents within 90 days before randomization.
  • Prior exposure to gene therapy or prior bone marrow or stem cell transplantation, including any conditioning regimen.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Tebapivat 2.5 milligrams (mg)

    Participants will receive 2.5 mg tebapivat orally, once daily (QD) for 12-weeks in the double-blind (DB) period. Participants who complete the DB Period will be eligible to receive the same dose in the Open-Label Extension (OLE) period for up to 52 weeks.

    Drug: Tebapivat

  • Experimental
    Tebapivat 5.0 mg

    Participants will receive 5.0 mg tebapivat orally, QD, for 12-weeks in the DB period. Participants who complete the DB Period will be eligible to receive the same dose in the OLE period for up to 52 weeks.

    Drug: Tebapivat

  • Experimental
    Tebapivat 7.5 mg

    Participants will receive 7.5 mg tebapivat orally, QD, for 12-weeks in the DB period. Participants who complete the DB Period will be eligible to receive the same dose in the OLE period for up to 52 weeks.

    Drug: Tebapivat

  • Placebo comparator
    Tebapivat Matched Placebo

    Participants will receive a matched placebo, orally, QD, for 12-weeks in the DB period. Participants who complete the DB Period will be randomized in 1:1:1 to receive tebapivat 2.5 mg QD, tebapivat 5.0 mg QD, or tebapivat 7.5 mg QD in the OLE period for up to 52 weeks

    Drug: Tebapivat · Drug: Tebapivat Matched Placebo

Interventions

  • Oral tablets.

    Also known as: AG-946

  • DrugTebapivat Matched Placebo

    Oral tablets.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Hb Response

    Time frame: Baseline, Week 10 through Week 12

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Up to Week 72

  2. Average Change From Baseline in Hb Concentration

    Time frame: Baseline, Week 10 through Week 12

  3. Average Change From Baseline in Indirect Bilirubin

    Time frame: Baseline, Week 10 through Week 12

  4. Average Change From Baseline in Lactate Dehydrogenase (LDH)

    Time frame: Baseline, Week 10 through Week 12

  5. Average Change From Baseline in Absolute Reticulocyte Count

    Time frame: Baseline, Week 10 through Week 12

  6. Average Change From Baseline in Percent Reticulocytes

    Time frame: Baseline, Week 10 through Week 12

  7. Average Change From Baseline in Erythropoietin

    Time frame: Baseline, Week 10 through Week 12

  8. Average Change From Baseline in Patient Reported Outcomes Measurement Information System® (PROMIS) Fatigue 13a Short Form Score

    Time frame: Baseline, Week 10 through Week 12

  9. Average Change From Baseline in PROMIS Pain Intensity 1a Score

    Time frame: Baseline, Week 10 through Week 12

  10. Average Change From Baseline in Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) Pain Impact Score

    Time frame: Baseline, Week 10 through Week 12

  11. Plasma Concentration of Tebapivat

    Time frame: Pre-dose and at multiple timepoints post-dose up to Week 8

  12. Maximum (Peak) Concentration (Cmax) of Tebapivat

    Time frame: Pre-dose and at multiple timepoints post-dose up to Week 8

  13. Time to Cmax (tmax) of Tebapivat

    Time frame: Pre-dose and at multiple timepoints post-dose up to Week 8

  14. Area Under the Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC0-t) of Tebapivat

    Time frame: Pre-dose and at multiple timepoints post-dose up to Week 8

  15. Whole Blood Concentrations of 2,3-Diphosphoglycerate (2,3-DPG)

    Time frame: Pre-dose and at multiple timepoints post-dose up to Week 8

  16. Whole Blood Concentrations of Adenosine Triphosphate (ATP)

    Time frame: Pre-dose and at multiple timepoints post-dose up to Week 8

07

Study locations

20 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in May 2026, 12 months.

Of 34 industry-sponsored phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 41. This study's 12 months is below that.

Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2025
First posted
Apr 13, 2025
StartActual
May 1, 2025
Primary completionActual
May 12, 2026
CompletionEst.
May 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Oct 28, 2026
Show all 2 updates
  1. Oct 28, 2026
    Minor edits only
    + 1 other change: verification date
  2. Sep 28, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06924970
Responsible party
Sponsor
First posted
Apr 13, 2025
Start date
May 1, 2025
Primary completion
May 12, 2026
Completion
May 2027 (estimated)
Last update
Oct 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tebapivat

Start the discussion